dc.contributor
Institut Català de la Salut
dc.contributor
[Gogas H] National and Kapodistrian University of Athens, Athens, Greece. [Ravimohan S, Datta A, Chhibber A] Bristol Myers Squibb, Princeton, NJ, USA. [Muñoz Couselo E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Diab A] MD Anderson Cancer Center, Houston, TX, USA
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
ravimohan, shruthi
dc.contributor.author
Datta, Antara
dc.contributor.author
Chhibber, Aparna
dc.contributor.author
Tallón de Lara, Paulino
dc.contributor.author
Gogas, Helen
dc.contributor.author
MUÑOZ COUSELO, EVA
dc.date.accessioned
2025-10-24T10:24:03Z
dc.date.available
2025-10-24T10:24:03Z
dc.date.issued
2024-07-29T11:35:45Z
dc.date.issued
2024-07-29T11:35:45Z
dc.date.issued
2024-07-19
dc.identifier
Gogas H, Ravimohan S, Datta A, Chhibber A, Muñoz Couselo E, Diab A, et al. Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab. npj Precis Oncol. 2024 Jul 19;8(1):150.
dc.identifier
https://hdl.handle.net/11351/11788
dc.identifier
10.1038/s41698-024-00641-7
dc.identifier.uri
https://hdl.handle.net/11351/11788
dc.description.abstract
Baseline biomarkers; Efficacy; Immune-profile
dc.description.abstract
Biomarcadores basales; Eficacia; Perfil inmunológico
dc.description.abstract
Biomarcadors basals; Eficàcia; Perfil immunològic
dc.description.abstract
In PIVOT IO 001 (NCT03635983), the combination of the investigational interleukin-2 agonist bempegaldesleukin (BEMPEG) with nivolumab (NIVO) had no added clinical benefit over NIVO monotherapy in unresectable/metastatic melanoma. Pre-defined baseline and on-treatment changes in selected biomarkers were analyzed to explore the potential mechanisms underlying the clinical observations. In each treatment arm, higher baseline tumor mutational burden or immune infiltration/inflammation was associated with improved efficacy compared with lower levels. On-treatment peripheral biomarker changes showed that BEMPEG + NIVO increased all immune cell subset counts interrogated, including regulatory T cells. This was followed by attenuation of the increase in CD8 + T cells, conventional CD4 + T cells, and systemic interferon gamma levels at later treatment cycles in the combination arm. Changes in tumor biomarkers were comparable between arms. These biomarker results help provide a better understanding of the mechanism of action of BEMPEG + NIVO and may help contextualize the clinical observations from PIVOT IO 001.
dc.format
application/pdf
dc.publisher
Nature Portfolio
dc.relation
NPJ precision oncology;8(1)
dc.relation
https://doi.org/10.1038/s41698-024-00641-7
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Quimioteràpia combinada
dc.subject
Medicaments antineoplàstics - Ús terapèutic
dc.subject
Melanoma - Tractament
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents
dc.subject
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Germ Cell and Embryonal::Neuroectodermal Tumors::Neuroendocrine Tumors::Melanoma
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos
dc.subject
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::tumores neuroendocrinos::melanoma
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
dc.title
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
